



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### Microbiota in Exhaled Breath Condensate and the Lung

**Citation for published version:**

Glendinning, L, Wright, S, Tennant, P, Gill, AC, Collie, D & McLachlan, G 2017, 'Microbiota in Exhaled Breath Condensate and the Lung', *Applied and Environmental Microbiology*, vol. 83, no. 12, UNSP e00515-17. <https://doi.org/10.1128/AEM.00515-17>

**Digital Object Identifier (DOI):**

[10.1128/AEM.00515-17](https://doi.org/10.1128/AEM.00515-17)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

Applied and Environmental Microbiology

**Publisher Rights Statement:**

Copyright © 2017 Glendinning et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



1 Microbiota in Exhaled Breath Condensate and the Lung

2 Laura Glendinning<sup>a</sup> #, Steven Wright<sup>a</sup>, Peter Tennant<sup>a</sup>, Andrew C. Gill<sup>a</sup>, David Collic<sup>a</sup>, Gerry  
3 McLachlan<sup>a</sup>

4

5 The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh,  
6 Edinburgh, Midlothian, United Kingdom<sup>a</sup>

7

8 Running title: Evaluation of EBC for lung microbiota sampling

9

10

11 # Address correspondence to Laura Glendinning, [Laura.Glendinning@roslin.ed.ac.uk](mailto:Laura.Glendinning@roslin.ed.ac.uk)

12

13 Abstract word count: Abstract = 245 words, Importance = 140 words

14 Main text word count: 5225 words

15    **Abstract**

16    The lung microbiota is commonly sampled using relatively invasive bronchoscopic procedures.  
17    Exhaled breath condensate (EBC) collection potentially offers a less invasive alternative for lung  
18    microbiota sampling. We compared lung microbiota samples retrieved by protected specimen  
19    brushings (PSB) and exhaled breath condensate collection. We also sought to assess whether  
20    aerosolised antibiotic treatment would influence the lung microbiota and whether EBC was  
21    sensitive enough to detect such changes.

22    EBC was collected from 6 conscious sheep, and then from the same anaesthetised sheep during  
23    mechanical ventilation. Following the latter EBC collection, PSB samples were collected from  
24    separate sites within each sheep lung. On the subsequent day each sheep was then treated with  
25    nebulised colistimethate sodium. Two days after nebulisation, EBC and PSB samples were again  
26    collected. Bacterial DNA was quantified using 16S rRNA gene qPCR. The V2-V3 region of the  
27    16S rRNA gene was amplified by PCR and sequenced using an Illumina Miseq. Quality control  
28    and operational taxonomic unit (OTU) clustering were performed within mothur.

29    EBC contained significantly less bacterial DNA than PSB samples. EBC samples from  
30    anaesthetised animals clustered separately by their bacterial community compositions in  
31    comparison to PSB samples and 37 bacterial OTUs were identified which were differentially  
32    abundant between the two sample types. Despite only low concentrations of colistin being  
33    detected in bronchoalveolar lavage fluid, PSB samples were found to differ by their bacterial  
34    compositions pre and post colistimethate sodium treatment. Our findings indicate that microbiota  
35    in EBC samples and PSB samples are not equivalent.

36 **Importance**

37 Sampling of the lung microbiota usually necessitates performing bronchoscopic procedures  
38 which involve a hospital visit for human participants and the use of trained staff. The  
39 inconvenience and perceived discomfort of participating in this kind of research may deter  
40 healthy volunteers and may not be a safe option for patients with advanced lung disease. This  
41 study set out to evaluate a less invasive method of collecting lung microbiota samples by  
42 comparing samples taken via protected specimen brushings (PSB) to those taken via exhaled  
43 breath condensate (EBC) collection. We found that there was less bacterial DNA in EBC  
44 samples compared to PSB samples and that there were differences between the bacterial  
45 communities in the two sample types. We conclude that while EBC and PSB samples do not  
46 produce equivalent microbiota samples, the study of the EBC microbiota may still be of interest.

## 47    **Introduction**

48    The study of the lung microbiota is a relatively new field in comparison to other areas of  
49    microbiota research. Although an increasing number of studies are linking changes in the  
50    composition of the lung bacterial communities to various disease states including allergies,  
51    autoimmune disorders and inflammatory and infectious diseases (1), protocols for studying the  
52    lung microbiota are not standardised, making comparisons between studies difficult.

53    One issue with studying the lung microbiota is the invasiveness of the sampling techniques; the  
54    most common techniques are bronchoalveolar lavage (BAL) and the collection of protected  
55    specimen brushings (PSB), both of which require the subject to undergo bronchoscopy. The  
56    inconvenience and fear of complications associated with bronchoscopic procedures can lead to  
57    healthy and/or diseased individuals declining to take part in studies (2), leading to a reduction in  
58    the potential pool of volunteers for lung microbiota studies. It is also currently unknown whether  
59    these sampling methods themselves can lead to changes in the lung microbiota.

60    Exhaled breath condensate (EBC) collection could potentially offer a less invasive method of  
61    taking lung microbiota samples. This method involves condensing exhaled vapour into a liquid  
62    and has previously been used to study exhaled bacteria, viruses and fungi (3-8). However, there  
63    have been no studies using 16S rRNA gene sequencing to compare the bacteria found in EBC  
64    samples to samples taken directly from the lungs. It is, therefore, not known whether it can be  
65    used as a surrogate for more invasive sampling techniques. We sought to assess the feasibility of  
66    using EBC in sheep to study the lung microbiota composition. We have previously used sheep as  
67    a model for studying the lung microbiota (9, 10) due to the anatomical and immunological  
68    similarity of their lungs to those of humans (11-13). In this study we compare EBC samples

69 collected from conscious sheep and from the same sheep under anaesthesia, to PSB samples  
70 taken from four spatially disparate sites within the lung.

71 We then extended this to address whether EBC analysis has the capacity to detect changes in  
72 bacterial community compositions by attempting to directly manipulate the lung microbiota with  
73 an inhaled antibiotic (colistimethate sodium (CMS): active against Gram-negative bacteria).  
74 During a previous study we examined the effect of intravenous CMS on the lung microbiota (9).  
75 Whilst we did identify changes in the lung microbiota composition, the longer term systemic  
76 antibiotic treatment used in this study is also likely to have affected the gut microbial  
77 populations. Immunological links between gut and lung immunity, the gut-lung axis, raise the  
78 possibility that such changes may have indirectly influenced the lung microbiota (14). In this  
79 study, we delivered nebulised CMS since this has been shown to lead to lower colistin plasma  
80 concentrations than injected CMS (15), enabling us to discern the direct effect of antibiotic  
81 treatment on respiratory bacterial communities.

82 A far greater quantity of bacterial DNA was isolated from PSB samples relative to EBC samples.  
83 We found that whilst there was some overlap between the types of bacteria found in these  
84 samples, EBC samples did cluster separately from PSB samples by their bacterial community  
85 compositions. Lastly, despite our antibiotic treatment regime only producing low concentrations  
86 of colistin in the lung epithelial lining fluids (the prodrug CMS is hydrolysed *in vivo* to the active  
87 form of the drug, colistin), significant differences in community composition were found  
88 between PSB samples derived pre- and post-treatment.

## 89    **Methods and materials**

### 90    **Animals**

91    Six commercially sourced, castrated, male Suffolk-cross sheep aged 14 months were used in this  
92    study. All animal experiments were approved by the Roslin Institute Animal Welfare and Ethics  
93    Committee and were subject to the Animals (Scientific Procedures) Act of 1986. Sheep had  
94    previously been housed outdoors as part of a large flock but were moved indoors before the  
95    study and remained indoors until the study end. Sheep were separated into two pens sharing the  
96    same airspace. One pen contained sheep ED951, ED952 and ED953 while the other contained  
97    sheep ED954, ED955 and ED956. The rectal temperatures and weights of all animals were taken  
98    prior to initial respiratory tract sampling. The animals weighed on average  $49.2 \pm 3.4$  kg (mean  $\pm$   
99    standard deviation (SD)) and rectal temperatures were measured as  $38.9 \pm 0.89^\circ\text{C}$ .

100

### 101    **Experimental design**

102    Conscious animals were confined in a yoke head restraint holding crate and EBC was collected  
103    for 10 mins using an RTubeVENT with cooling sleeve (Respiratory Research, Charlottesville,  
104    VA, USA) attached to a face mask. The sheep inhaled through a one-way inspiratory valve and  
105    expired through the RTubeVENT (**Figure 1**). The exhaled breath condensate samples from  
106    conscious sheep (EBC (cons)) were transferred from the RTubeVENT into Eppendorf tubes  
107    following the manufacturer's instructions and were frozen on dry ice within an hour of  
108    collection.

109    The sheep were then anaesthetised (3-5 hours later) following a procedure that has previously  
110    been described (16). Bronchoscopy was performed by use of an endotracheal tube. During

111 anaesthesia, EBC samples were collected for 10 mins by incorporating an RTubeVENT within  
112 the expiratory limb of the anaesthetic circuit (**Figure 1**). The condensate was again transferred  
113 into Eppendorf tubes. The exhaled breath condensate samples from the anaesthetised sheep (EBC  
114 (anaes)) were frozen on dry ice within an hour of collection. PSB samples (Disposable  
115 Microbiology Brush: ConMed, Utica, NY, USA) were taken from the left ventral diaphragmatic  
116 1 (LVD1), right ventral diaphragmatic 1 (RVD1), right caudal diaphragmatic (RCD) and left  
117 caudal diaphragmatic (LCD) lung segments (**Figure 2**). Brushes were cut into phosphate  
118 buffered saline (PBS: D8537, Sigma-Aldrich, Irvine, UK) for storage. For each sampling day, an  
119 unused protected specimen brush was cut into PBS to act as a control.

120 Eighteen hours after recovery from anaesthesia, sheep were administered 2,000,000 IU of CMS  
121 in 4 ml distilled water by inhalation (Colomycin for Injection: Forest Laboratories UK Ltd.,  
122 Dartford, UK). Restraint of the conscious sheep was as described above and the CMS was  
123 delivered using a face mask connected via the inspiratory limb to an eflow rapid nebuliser (PARI  
124 Respiratory Equipment Inc., Midlothian, VA, USA). This treatment was repeated 6 hours later.  
125 Two days after the first CMS dose was administered, EBC (cons), EBC (anaes) and PSB samples  
126 were again collected as described above. Sheep were killed by barbiturate overdose and  
127 exsanguination and blood samples were collected. Blood was centrifuged at 2500g for 5 mins  
128 and the serum was removed and frozen on dry ice. Immediately post-mortem, 20 ml aliquots of  
129 PBS were used to collect BAL fluid. The urea concentration in plasma and BAL fluid was used  
130 to calculate the dilution factor of lung epithelial lining fluid in BAL fluid (17).

131

### 132 **Quantitation of colistin in BAL fluid of sheep**



133 BAL fluid was centrifuged at 1400g for 5 mins to remove cells prior to colistin quantification.  
134 Quantitation of colistin in ovine BAL fluid essentially follows the method previously published  
135 by Marchand et al. (18). Briefly, colistin sulfate (Item no. 17584 (mixture of A and B isoforms):  
136 Cayman Chemicals, Ann Arbor, MI, USA) was dissolved in H<sub>2</sub>O to 1 mg/ml and a series of 7  
137 calibrant solutions were created by diluting the stock solution into blank BAL fluid to cover the  
138 range from 100 to 0.07 µg/ml. Polymyxin B (Sigma-Aldrich, Irvine, UK) was used as an internal  
139 standard and was dissolved in water to 300 µg/ml. 2 µl of internal standard was added to 200 µl  
140 of each of the calibrant solutions and to 200 µl of each of the test samples. 800 µl of H<sub>2</sub>O &  
141 0.1% (v/v) formic acid was added to each of the samples/calibrants and each was partially  
142 purified by binding to a DSC-18 SPE cartridge (Sigma-Aldrich, Irvine, UK), eluting with 400 µl  
143 MeOH & 0.1% (v/v) formic acid. The eluted fractions were dried under vacuum and  
144 reconstituted in 50 µl of H<sub>2</sub>O & 0.1% (v/v) formic acid for subsequent analysis.

145 All calibrants and samples were centrifuged at 13000g for 5 mins to pellet any precipitate and  
146 then were analysed by online LC-MS/MS in duplicate. 5 µl aliquots were injected onto an Ace  
147 Ultracore 2.5 SuperC18 HPLC column (75 x 2.1 mm) pre-equilibrated at 98% (v/v) buffer A,  
148 where HPLC buffer A was H<sub>2</sub>O with 0.1% (v/v) formic acid and 0.01% (v/v) trifluoroacetic acid,  
149 whilst HPLC buffer B was acetonitrile with 0.1% (v/v) formic acid and 0.01% (v/v)  
150 trifluoroacetic acid. The HPLC separation was developed by the following steps: from 2% buffer  
151 B on 0 mins to 18% buffer B on 1 min; 22% buffer B on 3.5 mins; 100% buffer B on 4 mins;  
152 100% buffer B on 5 mins and returning to 2% buffer B on 6 mins for 5 mins to re-equilibrate.  
153 The flow rate was 200 µl/min and the eluent was passed directly to the electrospray source of an  
154 Amazon ETD ion trap mass spectrometer (Bruker, Billerica, MA, USA) operated in positive ion  
155 mode. The mass spectrometer was operated under multiple reaction monitoring conditions, using

parent ions of 578.3, 585.3 and 602.3 (representing the double charged ion of colistin B, A and polymyxin B respectively), fragmentation amplitudes of 0.8 and cut offs of 140 in each case. Calibration curves and colistin concentrations were calculated by Bruker's proprietary software QuantAnalysis, using the following reporter ions: colistin A 526.3, 535.3, 567.3, 576.3; colistin B 519.3, 528.3, 560.800, 569.3; Polymyxin B 543.300, 552.300, 584.300, 593.3.

## **DNA extraction**

DNA extraction was carried out as described previously (10) using the MO BIO PowerSoil DNA Isolation Kit (MO BIO Laboratories inc., Carlsbad, CA, USA). All DNA extractions were carried out using the same lot of extraction kit, as the contamination present in different lots of the same make of kit have been shown not to be consistent (19). Samples were randomly assigned to one of four DNA extraction batches and for each of these batches an extraction kit reagent only control was produced (sample groupings can be found in **Dataset S1**).

## **16S rRNA gene amplification and sequencing**

The V2-V3 variable regions of the 16S gene were amplified as described previously (10). A nested PCR protocol was used in order to decrease the potential bias introduced by the use of barcoded primers by only including primers with Illumina adaptor sequences and barcodes in the second PCR round (20). The first round used the V1-V4 primers 28F ('5-GAGTTTGATCNTGGCTCAG-3') and 805R ('5-GACTACCAGGGTATCTAATC-3') and the second round used the V2-V3 primers 104F ('5-GGCGVACGGGTGAGTAA-3') and 519R ('5-GTNTTACNGCGGCKGCTG-3') with Illumina adaptor sequences and barcodes (**Dataset S1**).

178 The PCR conditions for the first round were 94°C for 2 min followed by 20 cycles of 94°C for 1  
179 min, 55°C for 45 s and 72°C for 1.5 min followed by 72°C for 20 min. The conditions for the  
180 second round were 98°C for 30 s followed by 20 cycles of 98°C for 10 s, 67°C for 30 s and 72°C  
181 for 10 s followed by 72°C for 2 min Q5 High-Fidelity 2X Master Mix (New England BioLabs.,  
182 Ipswich, MA, USA) was used for all reactions. After each PCR round, amplicons were purified  
183 using the AMPure XP PCR purification system (Beckman Coulter, Brea, CA, USA). The Human  
184 Microbiome Project Mock Community HM-783D (obtained through BEI Resources, NIAID,  
185 NIH) also underwent PCR alongside samples and controls. The Qubit dsDNA HS Assay Kit  
186 (Thermo Fisher Scientific, Hemel Hempstead, UK) was used to calculate the quantity of DNA in  
187 each sample then samples were pooled into a sequencing library. Sequencing was performed on  
188 an Illumina Miseq (Illumina, San Diego, CA, USA) producing 250bp paired-end reads.

189

#### 190 **Bioinformatic and statistical analysis**

191 Primers were removed with cutadapt (21) and sequences with greater than one base error per 10  
192 bases were discarded. Quality control, taxonomic assignment and OTU clustering were  
193 performed in mothur (22) as described previously (10). The data was subsampled to the  
194 minimum number of sequence reads found in one of our samples (11675). Except where stated,  
195 the following analyses were all performed within mothur.

196 Good's coverage values were calculated to estimate sample coverage (23). Distance matrices  
197 were constructed using Yue Clayton theta values (24) and analysis of molecular variance  
198 (AMOVA) was used to compare groups of samples by their bacterial composition (25).  
199 Homogeneity of molecular variance (HOMOVA) was used to compare groups by their variation

200 (26). Principle coordinate analysis (PCOA) graphs were constructed to visualise sample  
201 clustering. The mothur command corr.axes was used to correlate bacterial OTUs to the axes of  
202 the PCOA graphs using the Spearman's rank correlation coefficient ( $r$ ). The Bonferroni  
203 correction was used to correct for multiple statistical tests. The Inverse Simpson's index was  
204 employed to measure microbial diversity and the Chao 1 index was employed to measure  
205 richness. Metastats was used to identify OTUs which were significantly different between groups  
206 (27) except where more than two groups were compared in which case indicator analysis was  
207 used (28).

208 To compare groups statistically where data was non-parametric, the Mann-Whitney U test was  
209 used if the groups were independent and the Wilcoxon Signed Rank test was used where samples  
210 were related (performed in SPSS Statistics 21, IBM Analytics). Boxplots for qPCR data were  
211 constructed in SPSS. Heatmaps were constructed in R (Version 3.2.2, R Foundation for  
212 Statistical Computing (<https://www.R-project.org>)) using the packages gplots (29), heatplus (30),  
213 RColorBrewer (31) and Vegan (32).

214

## 215 **qPCR**

216 Quantification of the V3 region of the 16S rRNA gene was carried out using a previously  
217 described method (10). A standard curve was generated using DNA extracted from *Pseudomonas*  
218 *aeruginosa* strain PA0579 using 9 serial dilutions ranging from 14.2 ng/ $\mu$ l to  $1.42 \times 10^{-7}$  ng/ $\mu$ l  
219 (Quantified by the Qubit dsDNA HS Assay). The 0.142 ng/ $\mu$ l dilution served as a positive  
220 control for all qPCR reactions. The average CT value of no template controls was 28.7.

221 qPCR was performed using 1 µl of extracted DNA solution, the primers UniF340 (‘5-  
222 ACTCCTACGGGAGGCAGCAGT-3’) and UniR514 (‘5-ATTACCGCGGCTGCTGGC-3’) at a  
223 final concentration of 0.4 µM and the LightCycler 480 SYBR green I master mix (Roche  
224 Applied Science, Mannheim, Germany). The qPCR run consisted of a preincubation step (50°C  
225 for 2 min then 95°C for 10 s), an amplification step (45 cycles of 95°C for 30 s, then 63°C for 30  
226 s) and a melting cycle.

227

#### 228 **Data availability**

229 Sequencing reads can be accessed at Bioproject accession number PRJNA337937.

## 230 Results

### 231 Analysis of sequence quality and controls

232 DNA was extracted from respiratory samples and controls and the V2-V3 variable regions of the  
233 16S rRNA gene were amplified by PCR, then sequenced. After forming contigs from forward  
234 and reverse reads, various quality controls steps were undertaken which reduced the total  
235 sequence numbers by 25.8%. The lowest Good's coverage estimate value amongst the samples  
236 was 0.996 indicating that at least 99.6% of the bacteria in this sample were identified. The  
237 sequence error rate was 0.18% and the average number of reads per sample was  $39195 \pm 11535$   
238 (mean  $\pm$  SD). In total 867 OTUs were identified.

239 The Human Microbiome Project Mock Community HM-783D, containing the 16S rRNA genes  
240 of 20 bacterial species in staggered quantities and fixed ratios (1,000 to 1,000,000 copies per  
241 organism per  $\mu$ l), was processed alongside samples. Some biases were identified (**Dataset S2**).  
242 Three species were incorrectly identified to species level (*Acinetobacter baumannii* misidentified  
243 as *Acinetobacter rhizosphaerae*, *Clostridium beijerinckii* misidentified as *Clostridium butyricum*  
244 and *Neisseria meningitidis* misidentified as *Neisseria cinerea*). Two of the bacterial species  
245 which were present in low numbers in the original community were not identified at any  
246 taxonomic level: *Actinomyces odontolyticus* and *Bacteroides vulgatus*. Their absence is likely  
247 due to the fact that they were in low abundance rather than the inability of our protocol to  
248 amplify and identify them, as they have previously been identified using the same protocol on a  
249 non-staggered version of the same mock community (10). We were also previously able to  
250 identify *Enterococcus faecalis* to genus level whereas in this study it could not be identified  
251 except potentially as OTU 10: Bacilli (class). This discrepancy, combined with the fact that

252 *E.faecalis* is in low abundance in the staggered mock community leads us to believe that this  
253 identification is incorrect.

254 As lung bacteria are in low abundance, lung samples are at particular risk from contamination by  
255 bacterial DNA originating from DNA extraction kit reagents. Therefore, as well as mock  
256 community controls, DNA extraction kit reagent controls were produced. DNA was extracted  
257 from samples in four batches and a reagent control was included with every batch. The bacterial  
258 OTUs identified in extraction kit controls did not occur consistently in samples from the same  
259 batch (**Figure 3**). Samples did cluster by DNA extraction batch (AMOVA:  $P < 0.001$ ) and 30  
260 OTUs were found to be indicative of specific batches (**Dataset S3**). However, when these OTUs  
261 were removed from the dataset, samples still clustered by extraction batch (AMOVA:  $P = 0.014$ ),  
262 indicating that clustering was not entirely due to the presence of these OTUs. It is possible that  
263 some of these OTUs may be found naturally within the sheep respiratory system (eg.  
264 *Micrococcus luteus* – common coloniser of the human upper respiratory tract). We therefore  
265 decided not to remove these OTUs from our dataset. Since samples were randomly assigned to  
266 extraction batches, clustering by batch would be unlikely to lead to false positive statistical tests.  
267 However, there is the possibility that the presence of contaminating organisms may increase  
268 heterogeneity and thereby also increase stochastic noise.

269 In controls the most abundant OTUs on average were: PSB controls (*Corynebacterium*: 14.4%,  
270 Enterobacteriaceae: 10.9%, Intrasporangiaceae: 3.6%) and DNA extraction kit reagent controls  
271 (*Burkholderia*: 14.0%, Neisseriaceae: 10.5%, *Aggregatibacter*: 7.7%). The most abundant OTUs  
272 (on average) in the different sample types were: PSB samples (*Staphylococcus equorum*: 10.7%,  
273 *Mannheimia*: 6.5%, *Staphylococcus sciuri*: 5.6%), EBC (cons) (*Staphylococcus equorum*: 5.5%,

274 Neisseriaceae: 4.7%, *Paracoccus*: 4.3%) and EBC (anaes) (*Staphylococcus equorum*: 5.1%,  
275 *Staphylococcus epidermidis*: 3.7%, *Peptostreptococcus anaerobius*: 3.2%).

276

#### 277 **PSB samples contain more bacterial DNA than EBC samples**

278 The V3 region of the 16S rRNA gene was quantified in our samples using qPCR. On average,  
279 PSB samples contained  $1.53 \times 10^{-5} \pm 2.96 \times 10^{-5}$  ng/ $\mu$ l (mean  $\pm$  SD) bacterial DNA ( $34200 \pm$   
280  $66100$  16S copy numbers/ $\mu$ l) while EBC samples from conscious and anaesthetised sheep  
281 contained  $4.28 \times 10^{-7} \pm 5.34 \times 10^{-7}$  ng/ $\mu$ l ( $955 \pm 1190$  16S copy numbers/ $\mu$ l) and  $2.38 \times 10^{-7} \pm$   
282  $7.12 \times 10^{-8}$  ng/ $\mu$ l ( $531 \pm 159$  16S copy numbers/ $\mu$ l) respectively (**Figure 4**). DNA extraction kit  
283 reagent only controls contained  $1.82 \times 10^{-7} \pm 2.21 \times 10^{-8}$  ng/ $\mu$ l ( $406 \pm 49$  16S copy numbers/ $\mu$ l)  
284 while PSB controls and qPCR water controls contained  $1.84 \times 10^{-7} \pm 1.05 \times 10^{-8}$  ng/ $\mu$ l ( $411 \pm 23$   
285 16S copy numbers/ $\mu$ l) and  $1.98 \times 10^{-7} \pm 2.06 \times 10^{-8}$  ng/ $\mu$ l ( $442 \pm 46$  16S copy numbers/ $\mu$ l)  
286 respectively.

287 All respiratory samples contained significantly more DNA than controls (Mann-Whitney:  
288  $P < 0.005$  for all sample types). EBC samples from conscious and anaesthetised animals did not  
289 contain significantly different quantities of DNA (Wilcoxon signed-rank:  $P = 0.182$ ); however,  
290 PSB samples contained significantly more DNA when compared to both EBC (cons) (Wilcoxon  
291 signed-rank:  $P = 0.002$ ) and EBC (anaes) (Wilcoxon signed-rank:  $P = 0.002$ ) samples.

292

#### 293 **No significant clustering of EBC by sampling method**

294 Since EBC samples from conscious sheep would be expected to include more bacteria from the  
295 upper respiratory tract than EBC samples from anaesthetised sheep, it was expected that these



296 two groups of samples would cluster separately from one another. However, no significantly  
297 separate clustering was observed (AMOVA:  $P=0.994$ ). Despite this lack of separate clustering,  
298 EBC samples taken from the same sheep while it was conscious or anaesthetised did not contain  
299 the same bacterial communities, as can be observed in **Figure 5**.

300 The richness and diversity of bacterial communities were not significantly different between the  
301 two groups (Wilcoxon signed rank:  $P=0.583$ ,  $P=0.595$  respectively). When examined using  
302 metastats, there were significant differences in the quantities of several OTUs between these  
303 groups but all of these OTUs were present at low abundance ( $<1\%$  abundant on average in each  
304 group).

305

#### 306 **PSB samples and EBC (anaes) samples cluster separately by their bacterial communities**

307 We next investigated whether PSB and EBC samples contained equivalent bacterial  
308 communities. We compared PSB samples to EBC (anaes) samples as we hypothesised that these  
309 would be less likely to be contaminated by upper respiratory tract microbes than EBC (cons)  
310 samples. As well as containing a larger quantity of bacterial DNA, PSB samples also contained  
311 significantly different bacterial communities from EBC (anaes) samples (AMOVA:  $P=0.011$ ,  
312 **Figure 6**). This may be explained by the difference in variation between the two groups  
313 (HOMOVA:  $P=0.026$ ). Bacterial communities from PSB samples were also found to be  
314 significantly richer (Wilcoxon Signed Rank:  $P=0.006$ ) but there was no significant difference in  
315 diversity (Wilcoxon Signed Rank:  $P=0.48$ ). One OTU designated *Pseudomonas veronii*, which  
316 was the 4<sup>th</sup> most abundant OTU in PSB samples, was found to be significantly more abundant in  
317 PSB samples (Metastats  $q$ -value=0.046, PSB samples (mean  $\pm$  SD):  $3.9\% \pm 1.3\%$ , EBC: only

one sequence read found in one sample). The *P.veronii* OTU was not found in any of the PSB controls, indicating that it is likely that its presence is not due to contamination. This indicates that the EBC samples do not simply contain a subset of the most abundant OTUs from PSB samples. An additional 36 low abundance OTUs (<1% abundant on average in either group) were found to be significantly different between the two groups by Metastats.

We considered that, since EBC (anaes) samples contained far less bacterial DNA than PSB samples, they may have been more affected by contamination and this may be why these sample types cluster separately. However, the five most abundant OTUs found in DNA extraction kit reagent controls (*Burkholderia*, Neisseriaceae, *Aggregatibacter*, Pseudomonadaceae and *Methylobacterium*) were not found to be significantly differently represented between PSB samples and EBC (anaes) samples (Metastats q-value=1). It therefore seems unlikely that the separate clustering of these groups is due merely to the increased effect of contamination on EBC (anaes) samples.

### **Changes in the bacterial communities found in respiratory samples pre and post CMS treatment**

For both EBC (cons) and EBC (anaes) samples, pre and post treatment samples did not differ significantly by bacterial community structure (AMOVA: P=0.449, P=0.094 respectively). However, the bacterial communities found in PSB samples were found to be significantly different pre and post treatment (AMOVA: P=0.014, **Figure 7**). This significantly separate clustering was not merely due to differences in variation between the two groups (HOMOVA: P=0.87). The OTU *P.veronii* was increased in post treatment samples (Metastats q-value:

340 P=0.043, Pre-treatment (mean  $\pm$  SD): 0.74%  $\pm$  0.39%, Post-treatment: 7.1%  $\pm$  2.4%) and a  
341 further 97 low abundance (<0.1%) OTUs were found to significantly differentiate pre and post  
342 treatment samples.

343 Using the Wilcoxon signed rank test, it was found that the concentrations of DNA in respiratory  
344 samples pre and post CMS treatment did not differ significantly: PSB samples (P=0.689), EBC  
345 (cons) (P=0.345) and EBC (anaes) samples (P=0.248). The concentrations of colistin A  
346 identified in sheep lungs are shown in **Table 1**.

## 347 Discussion

348 In this study we sought to identify whether invasive lung microbiota sampling techniques could  
349 be replaced by a less invasive method. We compared the quantity of bacterial DNA and the  
350 bacterial communities from samples taken by PSB and EBC collection in six sheep at two  
351 sampling points. EBC was collected from both conscious and anaesthetised animals. During  
352 mechanical ventilation the animals were intubated, meaning that the exhaled breath collected was  
353 derived only from the lower respiratory tract; by comparing these samples to those taken from  
354 conscious animals it should be possible to analyse the extent of contamination by bacteria from  
355 the upper respiratory tract on EBC (cons) samples. We found that EBC samples contained  
356 significantly less bacterial DNA than PSB samples and that PSB samples clustered separately by  
357 the composition of their bacterial communities to EBC (anaes) samples. EBC (anaes) and EBC  
358 (cons) samples did not cluster separately from one another.

359 Studies examining the utility of EBC for identifying lung colonising microorganisms have shown  
360 variable results. A study comparing EBC and sputum samples from asthma patients showed a  
361 100% overlap in the culturable fungi identified between the two sample types (5) and a study  
362 examining the bacterial pathogens cultured from BAL and EBC samples in patients with  
363 ventilator associated pneumonia showed high concordance between the two sampling methods  
364 (33). In comparison, when PCR assays for ten common respiratory pathogens were performed on  
365 EBC and sputum samples from chronic obstructive pulmonary disease patients the results were  
366 found not to correlate well (34). EBC collection has also previously been found to be inefficient  
367 at detecting *Mycobacterium tuberculosis* (35), influenza viruses (36) and the common cystic  
368 fibrosis pathogens *Pseudomonas aeruginosa* and *Burkholderia cepacia* (37).

369 Some concerns have been raised about the use of EBC in respiratory research since the epithelial  
370 lining fluid contained in these samples is often variable and is very highly diluted with water  
371 vapour (38). This dilution could explain the far lower concentrations of bacterial DNA we  
372 identified in EBC samples in comparison to PSB samples. It is also likely that PSBs would be  
373 more efficient at sampling biofilms adhered to the lung mucosa which could explain some of the  
374 differences observed between the two sample types. The difference between the bacterial  
375 communities found in PSB samples and EBC may also be partially explained by how EBC is  
376 formed. The exact origin of EBC is still under debate but it has been suggested that differences  
377 observed between BAL and EBC samples could be explained by the fact that they sample  
378 different compartments of the lung (39). Whilst it might be assumed that EBC would be derived  
379 from both the central and peripheral airway compartments, which would perhaps explain the  
380 differences between these samples and PSB samples, Bondesson et al. conclude that the majority  
381 of EBC is in fact derived from the central airways (40). Without a better understanding of how  
382 EBC is formed and what influences its composition, we are unable to account for the differences  
383 we observed between the two sampling types.

384 Despite the fact that the concentrations of colistin found in the lungs were quite low after  
385 nebulised CMS treatment, a significant difference was observed in the bacterial communities  
386 from PSB samples pre and post treatment. In a previous study we found that the relative  
387 proportion of Gram negative bacteria in the lung microbiota was reduced post injected CMS  
388 treatment (excluding Pseudomonadales) (9). However, members of the Pseudomonadales  
389 generally increased in relative abundance or remained stable after treatment. It is therefore  
390 interesting to note that whilst in this study we did not find a significant reduction in the  
391 abundance of Gram negative bacteria in PSB samples (data not shown), an OTU belonging to the

392 Pseudomonadales (*P.veronii*) was significantly increased in these samples post CMS treatment.  
393 It is possible that even at low concentrations the colistin may have had some effect on the lung  
394 bacteria or that the sampling strategy may itself in some way lead to changes in the lung  
395 microbiota, but at the moment this is purely speculative. All samples were randomised prior to  
396 DNA extraction and PCR amplification therefore observed differences were not due to samples  
397 from one time-point being processed separately from those from the other time-point.

398 In conclusion, the differences we observe between PSB samples and EBC samples lead us to not  
399 recommend using EBC collection as a replacement for more invasive lung sampling techniques.  
400 However, the EBC microbiota may still be an interesting avenue of study despite the fact that the  
401 small quantities of bacterial DNA in these samples does leave them more vulnerable to  
402 contamination and any future studies would have to be designed with this in mind.

403    **Funding information**

404    Funding for this study was supplied by the BBSRC (Biotechnology and Biological Sciences  
405    Research Council, UK) under the EASTBIO doctoral training program (Grant number:  
406    BB/J01446X/1) and, in part, by an Institute Strategic Programme Grant (BB/J004332/1) also  
407    from the BBSRC. The funders had no input on study design; data collection and interpretation or  
408    the decision to submit this study for publication.

409    **Acknowledgments**

410    The following reagent was obtained through BEI Resources, NIAID, NIH as part of the Human  
411    Microbiome Project: Genomic DNA from Microbial Mock Community B (Staggered, Low  
412    Concentration), v5.2L, for 16S rRNA Gene Sequencing, HM-783D. We would like to thank the  
413    staff of Dryden Animal Services for the care of our animals.



414 **References**

- 415 1. **Dickson RP, Erb-Downward JR, Martinez FJ, Huffnagle GB.** 2016. The microbiome  
416 and the respiratory tract. *Annu Rev Physiol* **78**:481-504.
- 417 2. **Martinsen EMH, Leiten EO, Bakke PS, Eagan TML, Gronseth R.** 2016. Participation  
418 in research bronchoscopy: A literature review. *Eur Respir J* **3**:29511.
- 419 3. **Xu Z, Shen F, Li X, Wu Y, Chen Q, Jie X, Yao M.** 2012. Molecular and microscopic  
420 analysis of bacteria and viruses in exhaled breath collected using a simple impaction and  
421 condensing method. *PLoS ONE* **7**:e41137.
- 422 4. **Bhimji A, Singer LG, Kumar D, Humar A, Pavan R, Zhang H, Rotstein C,**  
423 **Keshavjee S, Mazzulli T, Husain S.** 2016. Feasibility of detecting fungal DNA in  
424 exhaled breath condensate by the Luminex Multiplex xTAG Fungal PCR Assay in lung  
425 transplant recipients: A pilot study. *J Heart Lung Transplant* **35**:S37.
- 426 5. **Carpagnano GE, Malerba M, Lacedonia D, Susca A, Logrieco A, Carone M,**  
427 **Cotugno G, Palmiotti GA, Foschino-Barbaro MP.** 2016. Analysis of the fungal  
428 microbiome in exhaled breath condensate of patients with asthma. *Allergy Asthma Proc*  
429 **37**:E41-E46.
- 430 6. **Carpagnano GE, Lacedonia D, Palladino GP, Logrieco G, Crisetti E, Susca A,**  
431 **Logrieco A, Foschino-Barbaro MP.** 2014. *Aspergillus* spp. colonization in exhaled  
432 breath condensate of lung cancer patients from Puglia Region of Italy. *BMC Pulm Med*  
433 **14**:22.
- 434 7. **Carpagnano GE, Lacedonia D, Cotugno G, Depalo A, Palmiotti GA, Giuffreda E,**  
435 **Foschino Barbaro MP.** 2015. Exhaled fungal microbiome in asthma: Possible  
436 association with severity and control. *Eur Respir J* **46**:PA4004.

- 437 8. **McDevitt JJ, Koutrakis P, Ferguson ST, Wolfson JM, Fabian MP, Martins M,**  
438 **Pantelic J, Milton DK.** 2013. Development and performance evaluation of an exhaled-  
439 breath bioaerosol collector for influenza virus. *Aerosol Sci Tech* **47**:444-451.
- 440 9. **Collie D, Glendinning L, Govan J, Wright S, Thornton E, Tennant P, Doherty C,**  
441 **McLachlan G.** 2015. Lung microbiota changes associated with chronic *Pseudomonas*  
442 *aeruginosa* lung infection and the impact of intravenous colistimethate sodium. *PLoS*  
443 *ONE* **10**:e0142097.
- 444 10. **Glendinning L, Wright S, Pollock J, Tennant P, Collie D, McLachlan G.** 2016.  
445 Variability of the sheep lung microbiota. *Appl Environ Microbiol* **82**:3225-3238.
- 446 11. **Bouljihad M, Leipold HW.** 1994. An ultrastructural study of pulmonary bronchiolar and  
447 alveolar epithelium in sheep. *J Vet Med A* **41**:573-586.
- 448 12. **Griebel PJ, Entrican G, Rocchi M, Beskorwayne T, Davis WC.** 2007. Cross-reactivity  
449 of mAbs to human CD antigens with sheep leukocytes. *Vet Immunol Immunopathol*  
450 **119**:115-122.
- 451 13. **Scheerlinck JPY, Snibson KJ, Bowles VM, Sutton P.** 2008. Biomedical applications of  
452 sheep models: From asthma to vaccines. *Trends Biotechnol* **26**:259-266.
- 453 14. **Dickson RP, Morris A.** 2017. Macrolides, inflammation and the lung microbiome:  
454 Untangling the web of causality. *Thorax* **72**:10-12.
- 455 15. **Yapa SWS, Li J, Patel K, Wilson JW, Dooley MJ, George J, Clark D, Poole S,**  
456 **Williams E, Porter CJH, Nation RL, McIntosh MP.** 2014. Pulmonary and systemic  
457 pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis  
458 patients: Targeting advantage of inhalational administration. *Antimicrob Agents*  
459 *Chemother* **58**:2570-2579.

- 460 16. **Collie D, Govan J, Wright S, Thornton E, Tennant P, Smith S, Doherty C,**  
461 **McLachlan G.** 2013. A lung segmental model of chronic *Pseudomonas* infection in  
462 sheep. PLoS ONE **8**:e67677.
- 463 17. **Rennard SI, Basset G, Lecossier D, Odonnell KM, Pinkston P, Martin PG, Crystal**  
464 **RG.** 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea  
465 as marker of dilution. J Appl Physiol **60**:532-538.
- 466 18. **Marchand S, Gobin P, Brillault J, Baptista S, Adier C, Olivier J-C, Mimoz O, Couet**  
467 **W.** 2010. Aerosol therapy with colistin methanesulfonate: A biopharmaceutical issue  
468 illustrated in rats. Antimicrob Agents Chemother **54**:3702-3707.
- 469 19. **Salter SJ, Cox MJ, Turek EM, Calus ST, Cookson WO, Moffatt MF, Turner P,**  
470 **Parkhill J, Loman NJ, Walker AW.** 2014. Reagent and laboratory contamination can  
471 critically impact sequence-based microbiome analyses. BMC Biol **12**:87.
- 472 20. **Berry D, Ben Mahfoudh K, Wagner M, Loy A.** 2011. Barcoded primers used in  
473 multiplex amplicon pyrosequencing bias amplification. Appl Environ Microbiol **77**:7846-  
474 7849.
- 475 21. **Martin M.** 2011. Cutadapt removes adapter sequences from high-throughput sequencing  
476 reads. Embnetjournal **17**:10-12.
- 477 22. **Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski**  
478 **RA, Oakley BB, Parks DH, Robinson CJ, Sahl JW, Stres B, Thallinger GG, Van**  
479 **Horn DJ, Weber CF.** 2009. Introducing mothur: Open-source, platform-independent,  
480 community-supported software for describing and comparing microbial communities.  
481 Appl Environ Microbiol **75**:7537-7541.
- 482 23. **Esty WW.** 1986. The efficiency of Good's nonparametric coverage estimator. Ann Stat  
483 **14**:1257-1260.

- 484 24. **Yue JC, Clayton MK.** 2005. A similarity measure based on species proportions.  
485 Commun Stat-Theory Methods **34**:2123-2131.
- 486 25. **Excoffier L, Smouse PE, Quattro JM.** 1992. Analysis of molecular variance inferred  
487 from metric distances among DNA haplotypes: Application to human mitochondrial  
488 DNA restriction data. Genetics **131**:479-491.
- 489 26. **Stewart CN, Excoffier L.** 1996. Assessing population genetic structure and variability  
490 with RAPD data: Application to *Vaccinium macrocarpon* (American Cranberry). J Evol  
491 Biol **9**:153-171.
- 492 27. **Paulson J, Pop M, Bravo H.** 2011. Metastats: An improved statistical method for  
493 analysis of metagenomic data. Genome Biol **12**:P17.
- 494 28. **Dufrene M, Legendre P.** 1997. Species assemblages and indicator species: The need for  
495 a flexible asymmetrical approach. Ecol Monogr **67**:345-366.
- 496 29. **Warnes G, Bolker B, Bonebakker L, Gentleman R, Liaw W, Lumley T, Maechler**  
497 **M, Magnusson A, Moeller S, Schwartz M, Venables B.** 2015. gplots: Various R  
498 programming tools for plotting data, v2.17.0. <http://CRAN.R-project.org/package=gplots>.
- 499 30. **Ploner A.** 2015. Heatplus: Heatmaps with row and/or column covariates and colored  
500 clusters, v2.16.0. <https://github.com/alexploner/Heatplus>.
- 501 31. **Neuwirth E.** 2014. RColorBrewer: ColorBrewer palettes, v1.1-2. [http://CRAN.R-](http://CRAN.R-project.org/package=RColorBrewer)  
502 [project.org/package=RColorBrewer](http://CRAN.R-project.org/package=RColorBrewer).
- 503 32. **Oksanen J, Blanchet F, Kindt R, Legendre P, Minchin P, O'Hara R, Simpson G,**  
504 **Solymos P, Stevens M, Wagner H.** 2016. Vegan: Community ecology package, v2.3-  
505 4/r2988. <http://R-Forge.R-project.org/projects/vegan/>.
- 506 33. **May AK, Brady JS, Romano-Keeler J, Drake WP, Norris PR, Jenkins JM, Isaacs**  
507 **RJ, Boczko EM.** 2015. A pilot study of the noninvasive assessment of the lung

- 508 microbiota as a potential tool for the early diagnosis of ventilator-associated pneumonia.  
509 Chest **147**:1494-1502.
- 510 34. **Zakharkina T, Koczulla AR, Mardanova O, Hattesohl A, Bals R.** 2011. Detection of  
511 microorganisms in exhaled breath condensate during acute exacerbations of COPD.  
512 Respirology **16**:932-938.
- 513 35. **Jain R, Schriever CA, Danziger LH, Cho SH, Rubinstein I.** 2007. The IS6110  
514 repetitive DNA element of *Mycobacterium tuberculosis* is not detected in exhaled breath  
515 condensate of patients with active pulmonary tuberculosis. Respiration **74**:329-333.
- 516 36. **St George K, Fuschino ME, Mokhiber K, Triner W, Spivack SD.** 2010. Exhaled  
517 breath condensate appears to be an unsuitable specimen type for the detection of  
518 influenza viruses with nucleic acid-based methods. J Virol Methods **163**:144-146.
- 519 37. **Vogelberg C, Hirsch T, Rosen-Wolff A, Kerkmann ML, Leupold W.** 2003.  
520 *Pseudomonas aeruginosa* and *Burkholderia cepacia* cannot be detected by PCR in the  
521 breath condensate of patients with cystic fibrosis. Pediatr Pulmonol **36**:348-352.
- 522 38. **Effros RM, Dunning MB, Biller J, Shaker R.** 2004. The promise and perils of exhaled  
523 breath condensates. Am J Physiol-Lung Cell Mol Physiol **287**:L1073-L1080.
- 524 39. **Jackson AS, Sandrini A, Campbell C, Chow S, Thomas PS, Yates DH.** 2007.  
525 Comparison of biomarkers in exhaled breath condensate and bronchoalveolar lavage. Am  
526 J Respir Crit Care Med **175**:222-227.
- 527 40. **Bondesson E, Jansson LT, Bengtsson T, Wollmer P.** 2009. Exhaled breath condensate-  
528 site and mechanisms of formation. J Breath Res **3**:016005.
- 529
- 530

531 **Figure Legends**

532 **Figure 1:** A) EBC was collected from conscious animals while they were restrained in a yoke  
533 head restraint holding crate. A face mask was attached and sheep inhaled through a short tube  
534 with an inlet valve and exhaled through an RTubeVENT. B) EBC was collected from  
535 anaesthetised, mechanically ventilated animals by placing the RTubeVENT in-line with the  
536 expiratory limb of the ventilator, near to the sheep's head.

537 **Figure 2:** Diagram of the sheep lung. PSB samples were taken pre and post colistimethate  
538 sodium treatment from the RVD1 (right ventral diaphragmatic 1), LVD1 (left ventral  
539 diaphragmatic 1), RCD (right caudal diaphragmatic) and LCD (left caudal diaphragmatic) lung  
540 segments. Figure adapted with permission from previous work (16).

541 **Figure 3:** Heatmap showing samples grouped by batch, based upon the time DNA was extracted  
542 from the samples. Bacterial OTUs were included where they had an abundance of  $\geq 5\%$  in at least  
543 one sample. OTUs which were  $\geq 5\%$  abundant in a DNA extraction kit reagent control are  
544 indicated by colour (batch 1 = green, batch 2 = pink, batch 3 = blue and batch 4 = yellow). DNA  
545 extraction kit reagent controls are labelled as Extraction Kit Batch *n*. EBC samples from  
546 conscious and from anaesthetised sheep are labelled EBC (cons) and EBC (anaes) respectively.  
547 OTUs which were  $> 5\%$  abundant in an extraction kit control do not consistently appear in all  
548 samples in the same batch.

549 **Figure 4:** Boxplot showing the log 16S rRNA gene concentrations found in sheep respiratory  
550 samples (EBC samples from conscious and anaesthetised animals and PSB samples) and controls  
551 (protected specimen brushes, DNA extraction kit reagents and qPCR reagents). Outliers were  
552 defined by SPSS as either 'out' values (circles) or 'extreme' values (stars). PSB samples

553 contained significantly more bacterial DNA ( $P < 0.005$ ) than any other respiratory sample type or  
554 control.

555 **Figure 5:** Heatmap showing EBC samples grouped by sheep and time-point. DNA extraction kit  
556 reagent controls are labelled as Extraction Kit Batch *n*. EBC samples from conscious and from  
557 anaesthetised sheep are labelled EBC (cons) and EBC (anaes) respectively. Bacterial OTUs were  
558 included where they had an abundance of  $\geq 5\%$  in at least one sample. As can be observed, EBC  
559 samples taken from the same sheep when it was conscious and when it was anaesthetised did not  
560 necessarily contain the same bacterial OTUs.

561 **Figure 6:** PCOA graph showing the significantly separate clustering of EBC (anaes) and PSB  
562 samples from sheep (AMOVA:  $P = 0.011$ ), which may be due to the difference in variation  
563 between the two sample types (HOMOVA:  $P = 0.026$ ). The OTUs which most contributed to  
564 samples moving in a positive or negative direction along either axis and which had p-values of  
565  $< 0.00058$  (defined by the Bonferroni correction as 0.5 divided by the total number of OTUs),  
566 according to the corr.axes command within mothur, are listed. As this graph is only  
567 representative of 20.3% of the total variability present between samples, caution should be taken  
568 when interpreting how clustered sample groups appear.

569 **Figure 7:** PCOA graph showing the significantly separate clustering of PSB samples from sheep  
570 pre and post CMS treatment (AMOVA:  $P = 0.014$ ). The OTUs which most contributed to samples  
571 moving in a positive or negative direction along either axis and which had p-values of  $< 0.00058$   
572 (defined by the Bonferroni correction as 0.5 divided by the total number of OTUs), according to  
573 the corr.axes command within mothur, are listed. As this graph is only representative of 24% of  
574 the total variability present between samples, caution should be taken when interpreting how  
575 clustered sample groups appear.

576 **Tables**577 **Table 1: Colistin A concentrations in sheep epithelial lining fluid**

Sheep	Colistin A* concentration (Mean $\pm$ SD)	Dilution of epithelial lining fluid in BAL	Colistin A concentration corrected for dilution (Mean)
ED951	0.346 $\pm$ 0.056 ng/ $\mu$ l	5.45	1.89 ng/ $\mu$ l
ED952	0.320 $\pm$ 0.034 ng/ $\mu$ l	4.18	1.34 ng/ $\mu$ l
ED953	0.290 $\pm$ 0.061 ng/ $\mu$ l	6.45	1.87 ng/ $\mu$ l
ED954	1.549 $\pm$ 0.251 ng/ $\mu$ l	15.75	24.40 ng/ $\mu$ l
ED955	0.625 $\pm$ 0.159 ng/ $\mu$ l	11.43	7.15 ng/ $\mu$ l
ED956	0.222 $\pm$ 0.017 ng/ $\mu$ l	29.5	6.56 ng/ $\mu$ l

578 \*colistin B values were too low to be calculated accurately















